{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:40:44Z","timestamp":1793752844510,"version":"4.6.1"},"reference-count":86,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Chronic cough is a common symptom in patients with interstitial lung diseases (ILDs), which significantly affects health-related quality of life (HRQoL). The prevalence of chronic cough varies from 30% to almost 90% in different ILDs, with the highest rate in patients with idiopathic pulmonary fibrosis. However, the pathophysiology of cough in ILDs remains poorly understood, with multiple proposed mechanisms contributing to its development. This knowledge gap complicates both clinical assessment and treatment, as current therapeutic strategies target general cough mechanisms rather than ILD-specific pathways. This review synthesizes existing data to clarify distinct cough mechanisms across ILD subtypes and identify opportunities for more targeted therapeutic strategies in this challenging patient population. Moreover, cough can be a clinical marker of disease severity and a predictor of ILD progression and transplant-free survival. Effective cough-specific therapeutic options that consider potential mechanisms, comorbidities, and individual effects on HRQoL are needed for cough associated with ILD. Therefore, the aim of this review was to analyze the prevalence, the impact on HRQoL, the pathophysiology, and the management of chronic cough in ILDs. Methods: We performed a comprehensive search in PubMed, MEDLINE, Embase, and the Cochrane Library. This review included randomized clinical trials, observational studies, systematic reviews, and meta-analyses in adults with chronic cough comparing ILD types. The following were excluded: commentaries, letters, case reports and case series, conference abstracts, and studies and publications lacking cough-specific outcomes. Results: Several approaches to reduce cough frequency and severity were described: antifibrotic agents, neuromodulators, opiates, inhaled local anesthetics, oxygen, speech therapy, and anti-reflux therapy. Some therapeutic approaches, such as oral corticosteroids and thalidomide, can cause significant side effects. Novel agents, such as P2X3 receptor antagonists, which are in phase III trials (COUGH-1\/2), show promising results for refractory cough and may benefit ILD-related cough. Conclusions: Thus, a comprehensive assessment of cough is required for effective cough treatment in patients with ILDs considering possible mechanisms and individual impact on QoL.<\/jats:p>","DOI":"10.3390\/diagnostics15091139","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:05:57Z","timestamp":1745989557000},"page":"1139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases"],"prefix":"10.3390","volume":"15","author":[{"given":"Natalia V.","family":"Trushenko","sequence":"first","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"},{"name":"Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russia, Orekhovyy Boulevard 28, Moscow 115682, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9661-7213","authenticated-orcid":false,"given":"Olga A.","family":"Suvorova","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-0091","authenticated-orcid":false,"given":"Anna E.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-9388","authenticated-orcid":false,"given":"Svetlana Y.","family":"Chikina","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-2900","authenticated-orcid":false,"given":"Iuliia A.","family":"Levina","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1254-6863","authenticated-orcid":false,"given":"Baina B.","family":"Lavginova","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-2150","authenticated-orcid":false,"given":"Sergey N.","family":"Avdeev","sequence":"additional","affiliation":[{"name":"Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya St. 8, Build. 2, Moscow 119991, Russia"},{"name":"Pulmonology Scientific Research Institute, Federal Medical and Biological Agency of Russia, Orekhovyy Boulevard 28, Moscow 115682, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccm.2021.03.001","article-title":"Interstitial Lung Disease in 2020: A History of Progress","volume":"42","author":"Guler","year":"2021","journal-title":"Clin. Chest Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5152\/TurkThoracJ.2022.22017","article-title":"Clinical, Functional, and Prognostic Evaluation of Idiopathic Pulmonary Fibrosis, Connective Tissue Disease-Associated Interstitial Lung Disease, Interstitial Pneumonia with Autoimmune Features: A Single-Center Prospective Study","volume":"23","author":"Erol","year":"2022","journal-title":"Turk. Thorac. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1933878","DOI":"10.1080\/20018525.2021.1933878","article-title":"International multidisciplinary team discussions on the diagnosis of idiopathic non-specific interstitial pneumonia and the development of connective tissue disease","volume":"8","author":"Altraja","year":"2021","journal-title":"Eur. Clin. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/CM9.0000000000000256","article-title":"Clinical characteristics and outcomes of hypersensitivity pneumonitis: A population-based study in China","volume":"132","author":"Wang","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chikina, S., Cherniak, A., Merzhoeva, Z., Tyurin, I., Trushenko, N., Proshkina, A., Ataman, K., and Avdeev, S. (2023). Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment, Management and Outcomes. Life, 13.","DOI":"10.3390\/life13020435"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1183\/13993003.01369-2015","article-title":"Predictors of objective cough frequency in pulmonary sarcoidosis","volume":"47","author":"Sinha","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.2147\/IJGM.S391146","article-title":"Analysis of Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 161 Patients: A Retrospective Study","volume":"15","author":"Lu","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sato, R., Handa, T., Matsumoto, H., Kubo, T., and Hirai, T. (2019). Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: A cross-sectional study. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-1012-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/resp.13084","article-title":"Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases","volume":"22","author":"Cheng","year":"2017","journal-title":"Respirology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pupt.2015.10.009","article-title":"Cough in interstitial lung disease","volume":"35","author":"Garner","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_11","first-page":"575","article-title":"Chronic Cough: Evaluation and Management","volume":"96","author":"Michaudet","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chest.2022.03.025","article-title":"Pulmonary Fibrosis Foundation. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: Data from the Pulmonary Fibrosis Foundation patient registry","volume":"162","author":"Lee","year":"2022","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.202311-2101OC","article-title":"Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease","volume":"210","author":"Khor","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","article-title":"Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: A multicenter retrospective cohort study","volume":"158","author":"Zaman","year":"2020","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1440-1843.2011.01996.x","article-title":"Cough predicts prognosis in idiopathic pulmonary fibrosis","volume":"16","author":"Ryerson","year":"2011","journal-title":"Respirology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"00039","DOI":"10.1183\/23120541.00039-2023","article-title":"Understanding patient experience of chronic cough in interstitial lung disease","volume":"9","author":"Mann","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00408-024-00723-0","article-title":"Patient Perception of Cough in Interstitial Lung Disease; Impact of Cough Hypersensitivity","volume":"202","author":"Hirons","year":"2024","journal-title":"Lung"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1745-9974-7-2","article-title":"Mechanical induction of cough in Idiopathic Pulmonary Fibrosis","volume":"7","author":"Jones","year":"2011","journal-title":"Cough"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pupt.2019.03.008","article-title":"Idiopathic pulmonary fibrosis-associated cough: Mechanisms and management","volume":"56","author":"Myall","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.201508-1638OC","article-title":"Stretch-induced Activation of Transforming Growth Factor-\u03b21 in Pulmonary Fibrosis","volume":"194","author":"Froese","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11739-018-1960-5","article-title":"The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis","volume":"14","author":"Bargagli","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pupt.2004.09.029","article-title":"Idiopathic pulmonary fibrosis: A nervous cough?","volume":"17","author":"Harrison","year":"2004","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12931-017-0674-y","article-title":"Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies","volume":"18","author":"Schertel","year":"2017","journal-title":"Respir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-9974-10-3","article-title":"Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5B genotype","volume":"10","author":"Scholand","year":"2014","journal-title":"Cough"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1164\/rccm.201507-1322LE","article-title":"Mucins MUC5B and MUC5AC in distal airways and honeycomb spaces: Comparison among idiopathic pulmonary fibrosis\/usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonitis, and control lungs","volume":"193","author":"Conti","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1513\/AnnalsATS.202302-174OC","article-title":"The burden and impact of cough in patients with idiopathic pulmonary fibrosis: An analysis of the prospective observational PROFILE study","volume":"20","author":"Saunders","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.mcp.0000174249.07762.37","article-title":"Chronic cough in adults with interstitial lung disease","volume":"11","author":"Madison","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106309","DOI":"10.1016\/j.rmed.2021.106309","article-title":"Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: A population-based, case-control study","volume":"178","author":"Baqir","year":"2021","journal-title":"Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.18093\/0869-0189-2022-32-3-473-495","article-title":"Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis","volume":"32","author":"Avdeev","year":"2022","journal-title":"Pulmonologiya"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"00051","DOI":"10.1183\/23120541.00051-2018","article-title":"Reflux in idiopathic pulmonary fibrosis: Treatment informed by an integrated approach","volume":"4","author":"Jones","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1378\/chest.08-2569","article-title":"Airway involvement in sarcoidosis","volume":"136","author":"Polychronopoulos","year":"2009","journal-title":"Chest"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/SMJ.0b013e318213ec03","article-title":"Impact of tracheal mucosa involvement on clinical characteristics of sarcoidosis","volume":"104","year":"2011","journal-title":"South. Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1465-9921-11-156","article-title":"Neurotrophins and neurotrophin receptors in pulmonary sarcoidosis\u2014Granulomas as a source of expression","volume":"11","author":"Dagnell","year":"2010","journal-title":"Respir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-9974-6-4","article-title":"Objective cough frequency in idiopathic pulmonary fibrosis","volume":"6","author":"Key","year":"2010","journal-title":"Cough"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.21037\/jtd-23-1443","article-title":"Patients with idiopathic pulmonary fibrosis and refractory cough have traction bronchiectasis and distorted airway architecture: A retrospective case review study","volume":"16","author":"Yamamura","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-022-00370-w","article-title":"Cough hypersensitivity and chronic cough","volume":"8","author":"Chung","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1007\/s00408-007-9034-x","article-title":"Quality of life and psychosocial aspects of cough","volume":"186","author":"Brignall","year":"2008","journal-title":"Lung"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12931-024-02897-w","article-title":"The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: A systematic evidence synthesis","volume":"25","author":"Green","year":"2024","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Veit, T., Barnikel, M., Kneidinger, N., Munker, D., Arnold, P., Barton, J., Crispin, A., Milger, K., Behr, J., and Neurohr, C. (2023). Clinical impact of physical activity and cough on disease progression in fibrotic interstitial lung disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12113787"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.11-0801","article-title":"Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: Findings from the Scleroderma Lung Study","volume":"142","author":"Theodore","year":"2012","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: Results of Scleroderma Lung Study II","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Nagy, T., Toth, N.M., Palmer, E., Polivka, L., Csoma, B., Nagy, A., Eszes, N., Vincze, K., B\u00e1rczi, E., and Boh\u00e1cs, A. (2022). Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092129"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14799731221089319","DOI":"10.1177\/14799731221089319","article-title":"Management of cough in patients with idiopathic interstitial lung diseases in primary care","volume":"19","author":"Kosowan","year":"2022","journal-title":"Chron. Respir. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/imj.14837","article-title":"Understanding cough in interstitial lung disease: A cross-sectional study on the adequacy of treatment","volume":"51","author":"Lan","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1701157","DOI":"10.1183\/13993003.01157-2017","article-title":"Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis","volume":"50","author":"Birring","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chen, C.H., Lin, H.C., Wang, Y.H., Wang, C.Y., Lin, Y.S., and Lai, C.C. (2021). The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251636"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2300752","DOI":"10.1183\/13993003.00752-2023","article-title":"INBUILD Trial Investigators. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis","volume":"63","author":"Wijsenbeek","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S2213-2600(17)30310-7","article-title":"A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: A randomised, double-blind, proof-of-concept, phase 2 trial","volume":"5","author":"Birring","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.202106-1485OC","article-title":"Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: A multicenter, randomized, placebo-controlled study (SCENIC Trial)","volume":"205","author":"Martinez","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2796.1994.tb00798.x","article-title":"No effect of high-dose inhaled steroids in pulmonary sarcoidosis: A double-blind, placebo-controlled study","volume":"236","author":"Milman","year":"1994","journal-title":"J. Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1183\/09031936.99.13613519","article-title":"Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: A pilot study","volume":"13","author":"Greenhalgh","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_54","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"Baughman","year":"2002","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1378\/chest.116.2.424","article-title":"Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: A double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group","volume":"116","author":"Pietinalho","year":"1999","journal-title":"Chest"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.200304-597OC","article-title":"A study of the cough reflex in idiopathic pulmonary fibrosis","volume":"168","author":"Hilldrup","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1513\/AnnalsATS.202103-266OC","article-title":"Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: A randomized controlled crossover trial","volume":"18","author":"Guler","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-157-6-201209180-00003","article-title":"Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial","volume":"157","author":"Horton","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/thoraxjnl-2018-212102","article-title":"Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis","volume":"74","author":"Dutta","year":"2019","journal-title":"Thorax"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-9974-10-4","article-title":"Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: An intervention study","volume":"10","author":"Kilduff","year":"2014","journal-title":"Cough"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0194599812471817","article-title":"Use of specific neuromodulators in the treatment of chronic, idiopathic cough: A systematic review","volume":"148","author":"Cohen","year":"2013","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: A randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): Results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","article-title":"Chronic Cough in IPF Study Group. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial","volume":"7","author":"Martinez","year":"2021","journal-title":"Pulm. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","article-title":"Opiate therapy in chronic cough","volume":"175","author":"Morice","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-2600(23)00432-0","article-title":"Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): A prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial","volume":"12","author":"Wu","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"EVIDoa2300083","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chest.2020.01.049","article-title":"Ambulatory oxygen in fibrotic interstitial lung disease: A pilot, randomized, triple-blinded, sham-controlled trial","volume":"158","author":"Khor","year":"2020","journal-title":"Chest"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thoraxjnl-2016-208843","article-title":"Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: A multicentre randomised control trial","volume":"72","author":"Garrod","year":"2017","journal-title":"Thorax"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pupt.2016.08.001","article-title":"Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study","volume":"40","author":"Lavorini","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/SPC.0000000000000447","article-title":"Cough, an unresolved problem in interstitial lung diseases","volume":"13","author":"Wijsenbeek","year":"2019","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","article-title":"Treatment of interstitial lung disease-associated cough: CHEST guideline and expert panel report","volume":"154","author":"Birring","year":"2018","journal-title":"Chest"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/resp.13483","article-title":"Idiopathic chronic productive cough and response to open-label macrolide therapy: An observational study","volume":"24","author":"Martin","year":"2019","journal-title":"Respirology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1465-9921-14-125","article-title":"Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: A randomised controlled trial","volume":"14","author":"Berkhof","year":"2013","journal-title":"Respir. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.33590\/emjrespir\/10312904","article-title":"Nerves, cough, and idiopathic pulmonary fibrosis","volume":"3","author":"Harrison","year":"2015","journal-title":"EMJ Respir."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.chest.2021.05.071","article-title":"Managing cough in idiopathic pulmonary fibrosis","volume":"160","author":"Wakwaya","year":"2021","journal-title":"Chest"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.alit.2022.05.006","article-title":"A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough","volume":"71","author":"Niimi","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2X3 receptor antagonist (AF-219) in refractory chronic cough: A randomised, double-blind, placebo-controlled phase 2 study","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"key":"ref_79","first-page":"CD013067","article-title":"Speech and language therapy for management of chronic cough","volume":"7","author":"Slinger","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1378\/chest.15-1271","article-title":"Pregabalin and speech pathology combination therapy for refractory chronic cough: A randomized controlled trial","volume":"149","author":"Vertigan","year":"2016","journal-title":"Chest"},{"key":"ref_81","first-page":"389","article-title":"A non-pharmacological cough therapy for people with interstitial lung diseases: A case report","volume":"75","author":"Dasouki","year":"2023","journal-title":"Physiother. Can."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1183\/09031936.00218613","article-title":"Expert opinion on the cough hypersensitivity syndrome in respiratory medicine","volume":"44","author":"Morice","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"210127","DOI":"10.1183\/16000617.0127-2021","article-title":"Chronic cough: New insights and future prospects","volume":"30","author":"Morice","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1378\/chest.12-1533","article-title":"Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: A case series","volume":"143","author":"Lim","year":"2013","journal-title":"Chest"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jaip.2020.11.037","article-title":"A randomized controlled trial to assess the effect of lidocaine administered via throat spray and nebulization in patients with refractory chronic cough","volume":"9","author":"Abdulqawi","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chest.2024.05.015","article-title":"Benefit-risk profile of P2X3 receptor antagonists for treatment of chronic cough: Dose-response model-based network meta-analysis","volume":"166","author":"Yamamoto","year":"2024","journal-title":"Chest"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/9\/1139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:28Z","timestamp":1760030668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/9\/1139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":86,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["diagnostics15091139"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15091139","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}